Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biosun quadrivalent HPV vaccine versus Gardasil in healthy adults
IRCT20230508058114N1Phase 3Completed
- Sponsor
- BioSun Pharmed
- Start
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of qHPV vaccine in human papillomavirus infection and Cervical Cancer (CC) (2 arms), sponsored by BioSun Pharmed. Primary endpoints: Antibody titer against HPV types 6, 11, 16, and 18 and Safety. Started Jun 2023; status: completed.
02
Drugs
qHPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on IRCT20230508058114N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230508058114N1.